Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2026)

Catalyst Pharmaceuticals' Long-Term Investments history runs 6 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• Quarterly Long-Term Investments rose 12.71% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.3 million (up 12.71% YoY) and the FY2025 annual result came in at $22.5 million, up 4.51% from the prior year.
• Long-Term Investments was $27.3 million for Q1 2026 at Catalyst Pharmaceuticals, up from $22.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $27.3 million in Q1 2026 and bottomed at $12.9 million in Q3 2023.
• A 4-year average of $19.0 million and a median of $19.2 million in 2025 frame the typical range for Long-Term Investments.
• Peak annual rise in Long-Term Investments reached 62.47% in 2025, while the deepest fall reached 4.51% in 2025.
• Catalyst Pharmaceuticals' Long-Term Investments stood at $16.5 million in 2023, then soared by 30.78% to $21.6 million in 2024, then gained by 4.51% to $22.5 million in 2025, then rose by 21.08% to $27.3 million in 2026.
• Business Quant data shows CPRX's Long-Term Investments at $27.3 million in Q1 2026, $22.5 million in Q4 2025, and $19.2 million in Q3 2025.